Thoracic tumor
Conditions
Interventions
Dexamethasone group:Under direct thoracoscopic guidance, 0.1 mg/kg dexamethasone compounded with 0.375% ropivacaine 20 ml was injected into the paravertebral space between the thoracic 5 and 6 vertebr
Sufentanil group:Under direct thoracoscopic guidance, 0.2ug/kg sufentanil compounded with 0.375% ropivacaine 20ml was injected into the paravertebral space between the thoracic 5 and 6 vertebrae
Dexmedetomidine group:Under direct thoracoscopic guidance, 0.5ug/kg dexmedetomidine compounded with 0.375% ropivacaine 20 ml was injected into the paravertebral interspace between the thoracic 5 and 6
Aceketamine group:Under direct thoracoscopic guidance, 0.25 mg/kg esketamine compounded with 20 ml of 0.375% ropivacaine was injected into the paravertebral interspaces between the thoracic 5 and 6 ve
Sponsors
Ningbo Medical Center Li Huili Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients undergoing elective thoracoscopic lobectomy. Patients aged 20-75 years, American Society of Anaesthesiologists (ASA) class I-II, no neurological or muscular disorders, no spinal deformity, fracture, trauma or surgical history, who agreed to participate in this study.
Exclusion criteria
Exclusion criteria: Allergy to ropivacaine, dexamethasone, sufentanil, dexmedetomidine, and esketamine, coagulation abnormalities, history of spinal deformity, fracture, trauma, or surgery, history of thoracic aortic aneurysm, those who had a mid-operative thoracotomy, those who had severe adhesions in the thoracic cavity, and those who did not co-operate with or asked to withdraw from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rest and exercise (deep breathing or coughing) NRS score and Ramsay sedation score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of sensory blockade;Postoperative analgesia;Time to first postoperative bed movement, time to drain removal, postoperative hospital stay; | — |
Countries
China
Contacts
Public ContactWU KEWEI
Li Huili Hospital, Ningbo Medical Centre
Outcome results
None listed